Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis of head-to-head randomized controlled trials

Depression and Anxiety

Volumn 31, Issue 8, 2014, Pages 641-652

  Romanelli, Robert J ^a   Wu, Frances M ^b   Gamba, Ryan ^c   Mojtabai, Ramin ^d   Segal, Jodi B ^e  

^a Clinical Outcomes Research   (United States)

^b Research   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

behavioral therapy; cognitive behavioral therapy; exposure and response ritual prevention; meta analysis; obsessive compulsive disorder; pharmacotherapy; serotonin reuptake inhibitors; systematic review

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

BEHAVIOR THERAPY; DATA SYNTHESIS; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PATIENT INFORMATION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; YALE BROWN OBSESSIVE COMPULSIVE SCALE; OBSESSIVE-COMPULSIVE DISORDER; PROCEDURES; STATISTICS AND NUMERICAL DATA;

BEHAVIOR THERAPY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 84905440230     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22232     Document Type: Review

References (43)

1. Simpson HB,. Pharmacological treatment of obsessive-compulsive disorder. In:, Stein MB, Steckler T, editors. Behavioral Neurobiology of Anxiety and Its Treatment. New York, NY: Springer Science and Business Media; 2010: 527-543.
2. Franklin ME, Foa EB,. Treatment of obsessive compulsive disorder. Annu Rev Clin Psychol 2011; 7: 229-243.
3. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2012; 51 (1): 98-113.
4. Lambert M,. Practice guidelines: APA releases guidelines on treating obsessive-compulsive disorder. Am Fam Physician 2008; 78 (1): 131-135.
5. Koran LM, Hanna GL, Hollander E, et al. Practice guidelines for the treatment of obsessive-compulsive disorder. Am Psychol Assoc 2007; 164 (7 Suppl): 5-53.
6. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M,. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008 (1): CD001765.
7. O'Kearney RT, Anstey KJ, von Sanden C,. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database Syst Rev 2006 (4): CD004856.
8. Gava I, Barbui C, Aguglia E, et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2007 (2): CD005333.
9. Abramowitz JS,. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997; 65 (1): 44-52.
10. Foa EB, Franklin ME, Moser J,. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination ? Biol Psychiatry 2002; 52 (10): 987-997.
11. Cuijpers P., Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF, 3rd,. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry 2013; 12 (2): 137-148.
12. Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P,. Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety ? Depress Anxiety 2011; 28 (7): 560-567.
13. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ,. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology 1998; 136 (3): 205-216.
14. Abramowitz JS, Whiteside SP, Deacon BJ,. The effectiveness of treatment for pediatric obsessive-compulsive disorder: a meta-analysis. Behav Ther 2005; 36: 55-63.
15. Watson HJ, Rees CS,. Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder (English). J Child Psychol Psychiatry 2008; 49 (5): 489-498.
16. Waldmeier PC, Baumann P, Greengrass PM, Maitre L,. Effects of clomipramine and other tricyclic antidepressants on biogenic amine uptake and turnover. Postgrad Med J 1976; 52 (3 Suppl): 33-39.
17. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration. Available at: www.cochrane-handbook.com
18. Choi Y,. Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurs Pract 2009; 21 (4): 207-213.
19. Piccinelli M, Pini S, Bellantuono C, Wilkinson G,. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995; 166 (4): 424-443.
20. Pigott TA, Seay SM,. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60 (2): 101-106.
21. Liu X, Liu J, Long J,. Paroxetine combined with cognitive behavior therapy in treatment of obsessive-compulsive disorder. Chin J Health Psychol 2005;(2): 86-87.
22. de Haan E, Hoogduin KA, Buitelaar JK, Keijsers GP,. Behavior therapy versus clomipramine for the treatment of obsessive-compulsive disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37 (10): 1022-1029.
23. Pediatric OCDTST. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the pediatric OCD treatment study (POTS) randomized controlled trial (English). J Am Med Assoc 2004; 292 (16): 1969-1976.
24. Asbahr FR, Castillo AR, Ito LM, Latorre MR, Moreira MN, Lotufo-Neto F,. Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2005; 44 (11): 1128-1136.
25. Franklin ME, Sapyta J, Freeman JB, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the pediatric OCD treatment study II (POTS II) randomized controlled trial. J Am Med Assoc 2011; 306 (11): 1224-1232.
26. Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990; 5 (1): 17-30.
27. de Haan E, van Oppen P, van Balkom AJ, Spinhoven P, Hoogduin KA, Van Dyck R,. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatry Scand 1997; 96 (5): 354-361.
28. Nakatani E, Nakagawa A, Nakao T, et al. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder-effectiveness of behavior therapy and fluvoxamine. Psychother Psychosom 2005; 74 (5): 269-276.
29. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162 (1): 151-161.
30. O'Connor KP, Aardema F, Robillard S, et al. Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatry Scand 2006; 113 (5): 408-419.
31. Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV,. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder (English). J Clin Psychiatry 2006; 67 (7): 1133-1139.
32. Hoexter MQ, de Souza Duran FL, D'Alcante CC, et al. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial. Neuropsychopharmacology 2012; 37 (3): 734-745.
33. Belotto-Silva C, Diniz JB, Malavazzi DM, et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord 2012; 26 (1): 25-31.
34. van Balkom AJLM, de Haan E, van Oppen P, Spinhoven P, Hoogduin KAL, van Dyck R,. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998; 186 (8): 492-499.
35. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR,. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry 2006; 67 (2): 269-276.
36. Hohagen F, Winkelmann G, Rasche-Ruchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results: of a multicentre study. Br J Psychiatry Suppl 1998 (35): 71-78.
37. Nazari H, Momeni N, Jariani M, Tarrahi MJ,. Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder. Int J Psychiatry Clin Pract 2011; 15 (4): 270-274.
38. Shareh H, Gharraee B, Atef-Vahid MK, Eftekhar M,. Metacognitive therapy (MCT), fluvoxamine, and combined treatment in improving obsessive-compulsive, depressive and anxiety symptoms in patients with obsessive-compulsive disorder (OCD). Iran J Psychiatry Behav Sci 2010; 4 (2): 17-25.
39. Rachman S, Cobb J, Grey S, et al. The behavioural treatment of obsessional-compulsive disorders, with and without clomipramine. Behav Res Ther 1979; 17 (5): 467-478.
40. Overbeek T, Schruers K, Vermetten E, Griez E,. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry 2002; 63 (12): 1106-1112.
41. Quarantini LC, Torres AR, Sampaio AS, et al. Comorbid major depression in obsessive-compulsive disorder patients. Compr Psychiatry 2011; 52 (4): 386-393.
42. Cottraux J, Messy P, Marks IM, Mollard E, Bouvard M,. Predictive factors in the treatment of obsessive-compulsive disorders with fluvoxamine and/or behaviour therapy. Behav Psychother 1993; 21 (1): 45-50.
43. Borges CP, Meyer E, Ferrao YA, Souza FP, Sousa MB, Cordioli AV,. Cognitive-behavioral group therapy versus sertraline for obsessive-compulsive disorder: five-year follow-up. Psychother Psychosom 2011; 80 (4): 249-250.